298 related articles for article (PubMed ID: 17110632)
1. Bone loss and fracture risk associated with cancer therapy.
Guise TA
Oncologist; 2006; 11(10):1121-31. PubMed ID: 17110632
[TBL] [Abstract][Full Text] [Related]
2. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
3. Adverse bone effects during pharmacological breast cancer therapy.
Bjarnason NH; Hitz M; Jorgensen NR; Vestergaard P
Acta Oncol; 2008; 47(4):747-54. PubMed ID: 18465344
[TBL] [Abstract][Full Text] [Related]
4. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
De Nijs RN
Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
7. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
8. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
9. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Brufsky AM
Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
[TBL] [Abstract][Full Text] [Related]
10. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
Saad F; Perrotte P; Bénard F; McCormack M; Karakiewicz PI
Can J Urol; 2005 Jun; 12 Suppl 2():9-15. PubMed ID: 16018826
[TBL] [Abstract][Full Text] [Related]
11. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer.
Limburg CE
Oncol Nurs Forum; 2007 Jan; 34(1):55-63. PubMed ID: 17562633
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
13. Interventions to prevent loss of bone mineral density in women receiving chemotherapy for breast cancer.
Swenson KK; Henly SJ; Shapiro AC; Schroeder LM
Clin J Oncol Nurs; 2005 Apr; 9(2):177-84. PubMed ID: 15853161
[TBL] [Abstract][Full Text] [Related]
14. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
15. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
16. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
17. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Coleman RE; Body JJ; Gralow JR; Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
[TBL] [Abstract][Full Text] [Related]
18. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for the management of cancer treatment induced bone loss.
Bertoldo F; Pancheri S; Zenari S; Boldini S
Expert Opin Emerg Drugs; 2010 Jun; 15(2):323-42. PubMed ID: 20377485
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
